Zyprexa documents ppt 1.

1. Zyprexa documents ppt 1. This powerpoint has a selection of pages from documents to do with marketing issues.

2. What are the “Zyprexa Documents” • Class action court case v Eli-Lilly re alleged with-holding of ADEs data (wght gain and diabetes) and off-label marketing (dementia and subsyndromal mood swings). • Subpoenaed internal company documents. • Lawyer (Gottstein), public health physician expert witness (Egilman), New York Times journalist (Berenson) December 2006. • 358 files, copious data re int memos, powerpoint pres, marketing strategies… • Website www.furiousseasons.com (Dawdy) and a German website. • Judge ordered cannot be retrieved from internet.

3. What are the “Zyprexa Documents” • Heavily downloaded from furiousseasons.com • Form basis of journalist articles and web-blog analyses. • Paper for academic literature (Spielmans) • Provide insight into the goals and functioning of a big pharmaceutical company.

4. Issues raised • Marketing for “NCE’s” (New Clinical Entities) and off-label indications. • Alternatively described as “Disease Mongering” to increase sales. • Damage control, use of “spin”, possible concealment re ADEs. • Sophistication of pharma companies in interacting with (controlling?) “customers”. = physicians, pharmacists, hospitals/govt, allied health, patient advocacy groups.

5. ZY100035541 Olanzapine Lifeplan • The “Safer Clozapine” • Market is Schizophrenia. • No mention of bipolar or dementia.

6. ZY100035541 Olanzapine Lifeplan

7. The “Safer Clozapine” Market is Schizophrenia. No mention of bipolar or dementia. ZY100035541 Olanzapine Lifeplan

8. ZY100035541 Olanzapine Lifeplan

9. Prozac patent due to expire August 2001. ZY201548768 Betting the Farm

10. ZY201548768 Betting the Farm

11. ZY200270343 Zyprexa Product Team summary 1997

12. ZY200270343 Zyprexa Product Team summary 1997

13. ZY200270343 Zyprexa Product Team summary 1997

14. ZY200270343 Zyprexa Product Team summary 1997

15. ZY200270343 Zyprexa Product Team summary 1997

16. ZY200270343 Zyprexa Product Team summary 1997

17. ZY200270343 Zyprexa Product Team summary 1997

18. ZY200270343 Zyprexa Product Team summary 1997

19. ZY200270343 Zyprexa Product Team summary 1997

20. ZY200270343 Zyprexa Product Team summary 1997

21. ZY200270343 Zyprexa Product Team summary 1997

22. ZY200270343 Zyprexa Product Team summary 1997

23. ZY200270343 Zyprexa Product Team summary 1997

24. ZY200270343 Zyprexa Product Team summary 1997

25. ZY100041262 PCP opportunity

26. ZY100041262 PCP opportunity

27. ZY100041262 PCP opportunity

28. ZY100520662 Zyprexa primary care briefing document 21July2000

29. ZY100520662 Zyprexa primary care briefing document 21July2000

30. ZY100520662 Zyprexa primary care briefing document 21July2000

31. ZY100520662 Zyprexa primary care briefing document 21July2000

32. ZY100520662 Zyprexa primary care briefing document 21July2000

33. ZY100582035 Zyprexa Complicated Mood Project date?

34. ZY201797499 email re driving depression story since 98 Feb 2000

36. ZY200083405 PCP vision

37. ZY200083405 PCP vision

38. ZY200083405 PCP vision

39. ZY200083405 PCP vision

40. ZY200083405 PCP vision

41. ZY100040886 Primary Care Physician strategy

42. ZY100040886 Primary Care Physician strategy

43. ZY100040886 Primary Care Physician strategy

44. ZY100040886 Primary Care Physician strategy

45. ZY200083622 Addressing PCP FAOC

46. ZY200083622 Addressing PCP FAOC

47. ZY200083622 Addressing PCP FAOC

48. ZY200083622 Addressing PCP FAOC

49. ZY 100175096Viva Zyprexa

50. ZY 100175096 Viva ZyprexaPCPs/GPs = financial opportunities